TIBET AIM PHARM. INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.62 CNY | +1.29% |
|
+8.70% | -27.38% |
| 26/04 | Tibet Aim Pharm. Inc. Proposes Final Dividend for 2023 | CI |
| 25/04 | Tibet AIM Pharm. Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| Sales 2022 | 857M 118M 9.86B | Sales 2023 | 667M 92.06M 7.68B | Capitalization | 2.26B 312M 26.04B |
|---|---|---|---|---|---|
| Net income 2022 | 44M 6.07M 506M | Net income 2023 | 15M 2.07M 173M | EV / Sales 2022 | 1.95 x |
| Net cash position 2022 | 271M 37.43M 3.12B | Net cash position 2023 | 375M 51.73M 4.31B | EV / Sales 2023 | 2.83 x |
| P/E ratio 2022 |
44.3
x | P/E ratio 2023 |
148
x | Employees | 447 |
| Yield 2022 |
0.98% | Yield 2023 |
-
| Free-Float | 62.16% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.29% | ||
| 1 week | +8.70% | ||
| Current month | -0.35% | ||
| 1 month | +3.98% | ||
| 3 months | -19.36% | ||
| 6 months | -21.42% | ||
| Current year | -27.38% |
1 week
7.54
8.71
1 month
6.988.95
Current year
5.5712.42
1 year
5.5713.28
3 years
5.5714.39
5 years
5.5716.80
10 years
5.5735.60
| Managers | Title | Age | Since |
|---|---|---|---|
Ke Xu
CEO | Chief Executive Officer | 46 | 01/10/01 |
Min Zhou
DFI | Director of Finance/CFO | 37 | 01/23/01 |
Ling Li
CHM | Chairman | 55 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Hu
BRD | Director/Board Member | 53 | 13/21/13 |
Zhan Zhou
BRD | Director/Board Member | 55 | 12/14/12 |
Qian Jin Li
IRC | Investor Relations Contact | 47 | 01/04/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 8.62 | +1.29% | 10,194,900 |
| 25/24/25 | 8.51 | +6.24% | 7,402,000 |
| 24/24/24 | 8.01 | +1.78% | 3,775,800 |
| 23/24/23 | 7.87 | +3.28% | 4,396,500 |
| 22/24/22 | 7.62 | -3.91% | 5,629,308 |
End-of-day quote Shenzhen S.E., April 26, 2024
More quotes
TIBET AIM PHARM INC is a China-based company principally engaged in the research, design, manufacture and distribution of chemical drugs and Chinese patent medicine. The Companyâs products include self-manufacturing medicine and third-party medicine. Self-manufacturing medicine includes miglitol tablets, hongjinxiaojie tablet, aceclofenac enteric-coated tablets, montmorillonite powder, as well as domperidone tablets, among others. Its third-party medicine includes gualoupi injection, nalmefene hydrochloride injection, oral liquid for children, cefotaxime sodium for injection, as well as carbetocin injection. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
17/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -27.38% | 227M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 002826 Stock
